- published: 27 May 2016
- views: 171
Cluster of differentiation antigen 135 (CD135) also known as Fms-like tyrosine kinase 3 (FLT-3), receptor-type tyrosine-protein kinase FLT3, or fetal liver kinase-2 (Flk2) is a protein that in humans is encoded by the FLT3 gene. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. CD135 is the receptor for the cytokine Flt3 ligand (FLT3L).
It is expressed on the surface of many hematopoietic progenitor cells. Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells.
The FLT3 gene is one of the most frequently mutated genes in acute myeloid leukemia (AML). Besides, high levels of wild-type FLT3 have been reported for blast cells of some AML patients without FLT3 mutations. These high levels may be associated with worse prognosis.
FLT3 is composed of five extracellular immunoglobulin-like domains, a transmembrane domain, a juxtamembrane domain and a tyrosine-kinase domain consisting of 2 lobes that are connected by a tyrosine-kinase insert. Cytoplasmic FLT3 undergoes glycosylation, which promotes localization of the receptor to the membrane.
The significance of FLT3 mutations in AML
Emerging Role of FLT3 Inhibitors in AML: Midostaurin
The Role of FLT3 Inhibitors in Acute Myeloid Leukemia
FLT3 mutations in AML
FLT3
FLT3 Mutation Status in AML
ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients
Flt3
FLT3
Richard Stone, MD: New FLT3 Inhibitor Crenolanib Shows Promise in FLT3-Mutated AML
Ali Bazarbachi, MD, from the American University of Beirut, Beirut, Lebanon provides an overview of FLT3 mutations in acute myeloid leukemia (AML) at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain. FLT3 is a tyrosine kinase and FLT3 mutations are seen in over 30% of AML patients according to Prof Bazarbachi. FLT3 mutations are associated with a poor prognosis and currently, researchers are investigating the use of tyrosine kinase inhibitors to target FLT3 mutations.
Raoul Tibes, MD, PhD, physician-scientist at the University Hospital Head Myeloid Malignancies, Department of Internal Medicine II at the University Hospital in Würzburg, and adjunct consultant at Mayo Clinic, discusses the role of FLT3 inhibitors in the treatment of patients with acute myeloid leukemia.
The FLT3 inhibitor crenolanib, when added to standard induction chemotherapy, was associated with high rates of minimal residual disease negativity in patients with FLT3-mutated acute myeloid leukemia. Dr. Stone shares results from the ongoing phase II trial.
this discussion is getting us nowherei almost forgot what
i came to say
could i be here tomorrow? will you be there today?
waiting and waiting what can we do? what do you believe
when time takes you?
almost forgot
time takes time takes you
have forgotten
take time time takes you
indecision breaks us or shall we stay frozen?
time is a host that guides us, or are we the prey to it?
another breathe, another minute has passed us by so
gently
i can't take back, can't take back, all those regrets
that live in me...
almost forgot
time takes time takes you
have forgotten
take time time takes you